MA28017A1 - Compositions ophtalmiques traitant l'hypertention oculaire - Google Patents

Compositions ophtalmiques traitant l'hypertention oculaire

Info

Publication number
MA28017A1
MA28017A1 MA28846A MA28846A MA28017A1 MA 28017 A1 MA28017 A1 MA 28017A1 MA 28846 A MA28846 A MA 28846A MA 28846 A MA28846 A MA 28846A MA 28017 A1 MA28017 A1 MA 28017A1
Authority
MA
Morocco
Prior art keywords
sub
hypertention
ophthalmic compositions
treating ocular
sup
Prior art date
Application number
MA28846A
Other languages
English (en)
Inventor
Meng Hsin Chen
James B Doherty
Luping Liu
Swaminathan Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28017A1 publication Critical patent/MA28017A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés ayant la formule (I) constituant de puissants bloquants de canal potassique ou des compositions desdits composés pour le traitement du glaucome et d'autres états conduisant à une pression intraoculaire élevée dans l'¿il d'un patient. L'invention concerne également l'emploi desdits composés pour réaliser un effet neuroprotecteur pour l'¿il d'un mammifère, particulièrement de l'homme, ou un sel pharmacologiquement acceptable, un ester hydrolysable in vitro, un énantiomère, un diastéréomère ou un mélange de ceux-ci. La formule (II) représente aryle en C6 à C10 ou hétérocyclyle en C3 à C10, ledit aryle ou hétérocyclyle pouvant être facultativement substitué avec 1 à 3 groupes choisis parmi Ra ; Z représente (CH2)nPO(OR)(OR*).
MA28846A 2003-09-04 2006-03-01 Compositions ophtalmiques traitant l'hypertention oculaire MA28017A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50009503P 2003-09-04 2003-09-04

Publications (1)

Publication Number Publication Date
MA28017A1 true MA28017A1 (fr) 2006-07-03

Family

ID=34312181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28846A MA28017A1 (fr) 2003-09-04 2006-03-01 Compositions ophtalmiques traitant l'hypertention oculaire

Country Status (20)

Country Link
US (1) US7410992B2 (fr)
EP (1) EP1663987B1 (fr)
JP (1) JP4546961B2 (fr)
KR (1) KR20060090801A (fr)
CN (2) CN1845904A (fr)
AT (1) ATE425971T1 (fr)
AU (1) AU2004272546B2 (fr)
BR (1) BRPI0414102A (fr)
CA (1) CA2537410C (fr)
DE (1) DE602004020079D1 (fr)
EC (1) ECSP066404A (fr)
IL (1) IL174068A0 (fr)
IS (1) IS8306A (fr)
MA (1) MA28017A1 (fr)
MX (1) MXPA06002515A (fr)
NO (1) NO20061505L (fr)
NZ (1) NZ545401A (fr)
RU (1) RU2006110625A (fr)
WO (1) WO2005026128A1 (fr)
ZA (1) ZA200601321B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574078A1 (fr) * 2004-07-20 2006-02-23 Merck & Co., Inc. Compositions ophtalmiques traitant l'hypertension oculaire
CA2792649A1 (fr) * 2010-03-26 2011-09-29 Michael Graeber Methodes et compositions ameliorees pour le traitement sur et efficace de la telangiectasie
CN103180731B (zh) * 2010-10-08 2015-09-09 阿克西斯股份有限公司 纤维肌痛症的诊断剂、诊断方法及治疗剂
WO2012139495A1 (fr) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de minéralocorticoïdes
CN110256314B (zh) * 2019-06-28 2020-12-15 南京林业大学 一种β-芳基酮类化合物的制备方法及其产品

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
WO1989010757A1 (fr) 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Nouvelle preparation ophtalmique pour le traitement de glaucomes
ES2062102T5 (es) 1988-09-06 2004-12-01 Pharmacia Ab Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
EP0724443A4 (fr) 1993-06-08 1997-09-10 Vide Pharmaceuticals Procedes et comositions d'abaissement de la pression intra-oculaire
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
ATE409491T1 (de) * 2000-01-18 2008-10-15 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
WO2001070702A1 (fr) 2000-03-17 2001-09-27 Alcon, Inc. Derives de 6-hydroxy-indazole destines au traitement du glaucome
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
EP1339678B1 (fr) 2000-11-27 2007-09-26 Pfizer Products Inc. Agonistes selectifs au recepteur ep4 dans le traitement de l'osteoporose
EP1515721A4 (fr) * 2002-06-14 2006-07-26 Merck & Co Inc Compositions ophthalmiques pour traiter l'hypertension oculaire
WO2004043354A2 (fr) * 2002-11-08 2004-05-27 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2537430A1 (fr) * 2003-09-04 2005-03-24 Merck & Co., Inc. Compositions ophtalmiques pour traiter l'hypertension oculaire

Also Published As

Publication number Publication date
ATE425971T1 (de) 2009-04-15
ZA200601321B (en) 2007-05-30
CA2537410A1 (fr) 2005-03-24
AU2004272546A1 (en) 2005-03-24
CN102558231B (zh) 2015-05-27
NZ545401A (en) 2008-10-31
IS8306A (is) 2006-02-16
BRPI0414102A (pt) 2006-10-31
WO2005026128A1 (fr) 2005-03-24
JP2007504233A (ja) 2007-03-01
IL174068A0 (en) 2006-08-01
CA2537410C (fr) 2009-08-11
EP1663987B1 (fr) 2009-03-18
RU2006110625A (ru) 2006-08-10
ECSP066404A (es) 2006-09-18
NO20061505L (no) 2006-04-27
US7410992B2 (en) 2008-08-12
CN1845904A (zh) 2006-10-11
KR20060090801A (ko) 2006-08-16
EP1663987A1 (fr) 2006-06-07
AU2004272546B2 (en) 2007-10-18
US20070010491A1 (en) 2007-01-11
CN102558231A (zh) 2012-07-11
MXPA06002515A (es) 2006-06-20
DE602004020079D1 (de) 2009-04-30
JP4546961B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
WO2005002520A3 (fr) Compositions ophtalmiques destinees au traitement d'hypertension oculaire
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
TW200740760A (en) Malonamide derivatives
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
WO2004103279A3 (fr) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles servant d'agonistes du recepteur s1p
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (fr) Compositions ophtalmiques pour le traitement de l'hypertension oculaire
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
SE0402925D0 (sv) Novel Compounds
NZ790364A (en) Compounds and compositions for use in treating skin disorders
DE69930271D1 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
WO2004043354A3 (fr) Compositions ophtalmiques pour traiter l'hypertension oculaire
WO2006044425A3 (fr) Compositions ophtalmiques de traitement de l'hypertension oculaire
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
MX2007006504A (es) Derivados de malonamida como inhibidores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer.
WO2007025897A3 (fr) Derives de benzooxazole, oxazolopyridine, benzothiazole et thiazolopyridine
MA28017A1 (fr) Compositions ophtalmiques traitant l'hypertention oculaire
CA2534634A1 (fr) Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
AU2012237066B2 (en) Pharmaceutical composition for preventing or treating macular degeneration
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
WO2006020003A3 (fr) Compositions ophtalmiques traitant l'hypertension oculaire